Dyadic International Inc (DYAI) Quote

$DYAI EMA Analysis: https://stockta.com/cgi-bin/analysis.pl?symb=DYAI&mode=table&table=ema

$DYAI - “We see this as a pivotal moment for Dyadic,” said Joe Hazelton, Dyadic’s President and COO. “We’ve proven the commercial readiness of our platforms with valuable partnerships and revenue. Now we’re aligning our organization to scale and expand across the life sciences, food, and nutrition markets. I look forward to working with our leadership team to work to accelerate this momentum, drive operational execution, and deliver tangible value to our shareholders.”

Dyadic’s C1 and Dapibus™ platforms—already central to its recent commercial successes—continue to underpin the Company’s strategy, offering differentiated, large-scale, high-titer production of recombinant proteins across targeted non-therapeutic markets.

While the significant majority of Dyadic’s focus will be on the compelling ancillary protein opportunity, legacy biopharmaceutical programs remain active, with Mr. Emalfarb (who will continue to serve as Chief Executive Officer and a member of the Board of Directors) overseeing their development in addition to his continued focus on funding/investment opportunities, IP strategy, and legacy projects.

READ MORE FULL INFO HERE - https://finance.yahoo.com/news/dyadic-announces-leadership-change-part-123500143.html

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
https://www.barchart.com/story/news/32167547/dyadic-to-report-first-quarter-2025-financial-results-on-wednesday-may-14-2025

more like rearranging the deck chairs (on the Titanic?)

$DYAI News Out! Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets

Leadership team realigned in order to enable execution of ancillary protein strategy

Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad

JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets. Dyadic’s Board of Directors, which has overseen and endorsed this strategy, has appointed Joe Hazelton as President, effective immediately. Mr. Hazelton will also continue in his role as Chief Operating Officer.

Over the past 18 months, Dyadic has made a deliberate pivot to prioritize near-term commercialization opportunities in high-growth, high-value segments such as cell culture media, DNA/RNA technologies, and non-animal food and nutrition ingredients. This pivot has achieved commercial validation through the consummation of high value transactions in the ancillary protein space, including a develop-and-commercialize partnership with Proliant Health and Biologicals for recombinant human albumin, a collaboration with a non-animal dairy enzyme company, and a joint venture with Fermbox Bio that led to the launch of EN3ZYME, recently resulting in a significant purchase order in the cellulosic enzyme market.

“We believe the achievement of these milestones validates our strategy and reflects the growing demand for ancillary recombinant proteins,” said Mark Emalfarb, Dyadic’s Founder and Chief Executive Officer. “We previously communicated an initial focus in the ancillary protein space, we have successfully executed on key initial agreements, and now we are reaffirming that focus by aligning our leadership team to accelerate growth. Joe’s appointment as President ensures focused and prioritized execution across Dyadic’s technical, operational and commercial efforts.”

As President, Joe Hazelton will be responsible for scaling Dyadic’s scientific and commercial initiatives, deepening industry partnerships, oversight of daily operations and ensuring efficient execution of the business strategy. In support of this strategic shift, Joe will also guide Dyadic’s corporate rebranding efforts.

“We see this as a pivotal moment for Dyadic,” said Joe Hazelton, Dyadic’s President and COO. “We’ve proven the commercial readiness of our platforms with valuable partnerships and revenue. Now we’re aligning our organization to scale and expand across the life sciences, food, and nutrition markets. I look forward to working with our leadership team to work to accelerate this momentum, drive operational execution, and deliver tangible value to our shareholders.”

https://finance.yahoo.com/news/dyadic-announces-leadership-change-part-123500143.html

$DYAI News : Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Expanded life science and industrial portfolio with six additional life science products in development

Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme markets

Up to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)

Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programs

Selected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.

Scientific Pre-Publication - "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1”

Cash, cash equivalents and investment-grade securities of $7.4 million as of March 31, 2025

Financial results and business update conference call scheduled for 5:00 pm ET today

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a biotechnology company specializing in the development of functional recombinant solutions and proprietary production strains to manufacture large quantities of precision-engineered proteins and enzymes for use in life science, nutrition, and industrial applications, today announced its financial results for the first quarter 2025, highlighting significant progress toward commercializing its proprietary Dapibus™ and C1 microbial protein production platforms and driving long-term growth opportunities.

"While we continue to support select biopharmaceutical initiatives through fully funded partnerships with organizations such as CEPI, the Gates Foundation, and Fondazione Biotecnopolo di Siena ("FBS”), our primary focus is on developing and commercializing scalable products with recurring revenue potential. This strategic pivot is aimed at driving sustainable growth in sectors with strong demand and clear market opportunities,” said Mark Emalfarb, CEO of Dyadic. "We believe we are making meaningful progress in returning to Dyadic's core strength, utilizing our proprietary microbial protein production platforms, like C1 and Dapibus, to drive revenue growth in high-value life sciences, bioactives, ingredients, and industrial markets such as cell culture media, nucleic and other enzymes.”

Mr. Emalfarb continued, "Looking ahead, Dyadic remains committed to expanding the reach of our C1 and Dapibus™ platforms by developing functional recombinant solutions for non-therapeutic applications that can be both commercialized and licensed. With a growing network of partners and increased support from non-dilutive funding sources, we believe Dyadic is well-positioned to advance innovation, broaden global access to affordable biologics, proteins and enzymes, and lower production costs, ultimately providing a stable foundation for long-term shareholder value.” https://finance.yahoo.com/news/dyadic-reports-first-quarter-2025-200500991.html

$DYAI Watch - Dyadic International, #NASDAQ Exciting Update! Wow! via
@YouTube

$DYAI Looking Toward Product Revenues

Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin and bovine alpha-lactalbumin. Dyadic’s partner is expected to first focus on research grade product, but will be able to expand into the excipient grade and current good manufacturing practices (cGMP) grade product as the market matures.

https://finance.yahoo.com/news/dyai-looking-toward-product-revenues-092700269.html

.$DYAI Dyadic’s partner is expected to first focus on research grade product, but will be able to expand into the excipient grade and current good manufacturing practices (cGMP) grade product as the market matures.

https://finance.yahoo.com/news/dyai-looking-toward-product-revenues-092700269.html

$DYAI Dyadic International: Proteins for World Health DYAI NASDAQ detailed its product portfolio, vaccines

$DYAI Buy Opinion from barchart https://www.barchart.com/stocks/quotes/DYAI/opinion

$ADMQ CEO INTERVIEW -

$DYAI Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical and bio-industrial products for human and animal health and alternative proteins.

https://dyadic.com/

$DYAI Barchart Buy Opinion - https://www.barchart.com/stocks/quotes/DYAI/opinion

DYAI, under $2

dyai...................https://stockcharts.com/h-sc/ui?s=dyai&p=W&b=5&g=0&id=p86431144783

DYAI................................https://stockcharts.com/h-sc/ui?s=DYAI&p=W&b=5&g=0&id=p86431144783

DYAI............................https://stockcharts.com/h-sc/ui?s=DYAI&p=W&b=5&g=0&id=p86431144783

DYAI under $2

$DYAI Dip buy opportunity -

$DYAI Looks oversold https://schrts.co/CyTyfmaA

$DYAI today provided an update on business progress and announced its attendance at the Bioprocess International Conference in Boston, September 23-26, 2024. https://finance.yahoo.com/news/dyadic-provides-alternative-proteins-business-135000115.html

$DYAI Traders cheat sheet https://www.barchart.com/stocks/quotes/DYAI/cheat-sheet

sounds good on paper, why can't they close a deal 🤔

$DYAI TECHNOLOGY Advantages and Opportunities
Speed
Stable Cell lines in ~7 weeks
Research Cell Bank becomes Master Cell Bank
No viral or endotoxin inactivation
3-7 day fermentation (continuous in development)
Productivity
Up to 300 times more productive than certain currently used vaccine cell lines
Up to 10 times more productive than certain currently used mammalian cell lines
Industrially proven platform that has run at up to 500,000L
Record levels of 10g/L of an antigen, >22 g/L of a monoclonal antibody
Cost
Industrial scale flexibility and scale
C1 can lower CAPEX:
Produce at smaller scale while dramatically increasing protein yields
Unparallelled productivity provides margin relief
C1 can lower OPEX
Smaller facility footprint and related costs
Industrial media costs for pharma grade materials

https://dyadic.com/science/advantages-and-opportunities/

DYAI under $2

show me the money!!!!!!!

$DYAI News! Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html

DYAI under $2

DYAI under $2

DYAI under $2

$DYAI Zacks SCR:
DYAI: Moo-Ve Over Bovines, C1'S Taking On Albumin

https://scr.zacks.com/news/news-details/2024/DYAI-Moo-ve-Over-Bovines-C1s-Taking-On-Albumin-article/default.aspx

standing by.

DYAI...................................https://stockcharts.com/h-sc/ui?s=DYAI&p=W&b=5&g=0&id=p86431144783

Dyadic International Inc. ( $DYAI ): Bird Flu Vaccine Development Amid Rising Pandemic Concerns


https://thestreetreports.com/dyadic-international-inc-dyai-bird-flu-vaccine-development-amid-rising-pandemic-concerns/

In response to this looming threat, the U.S. government has initiated discussions with Moderna (NASDAQ: MRNA) regarding an avian flu vaccine. Other companies, such as Pfizer (NYSE: PFE), Novavax (NASDAQ: NVAX), BioNTech (NASDAQ: BNTX), and Dyadic International Inc (NASDAQ: DYAI), may also be involved.

Outbreaks naturally cause concern, prompting companies to find solutions. On May 22, Australia reported its first human bird flu case, followed by a second U.S. case involving a Michigan farm worker. This surge in cases has spurred the U.S. government to engage with Moderna for vaccine development. Dyadic International Inc (NASDAQ: DYAI) is a key player to watch, given its proactive approach and promising bird flu vaccine candidate developed in collaboration with ViroVax.

Dyadic’s H5 bird flu vaccine candidate, offers significant advantages in terms of lower costs and accelerated manufacturing. Pre-clinical animal data ViroVax showed high neutralizing antibodies for three distinct H5 viruses, indicating its potential use in both cattle and humans. Scalability and flexibility are strengths of the Dyadic vaccine candidate, positioning it as a dynamic solution for a global health crisis.

The C1 production platform used by Dyadic is sustainable and cost-effective compared to MRNA and other vaccine production processes. This makes Dyadic International a crucial player in addressing the bird flu threat and ensuring preparedness for a potential outbreak.

DYAI under $3

$DYAI - "Dyadic International, Inc.’s (NASDAQ: DYAI) COO Joe Hazelton Discusses Expansion into Food and Beverage and the "Future of Foods" ..."

https://thestreetreports.com/dyadic-international-inc-s-nasdaq-dyai-coo-joe-hazelton-discusses-expansion-into-food-and-beverage-and-the-future-of-foods-on-the-street-reports-podcast-listen-now/

Dyadic International, Inc.’s (NASDAQ: DYAI) COO Joe Hazelton Discusses Expansion into Food and Beverage and the "Future of Foods" ...https://t.co/V9iubGRbEf— Dyadic International Inc. (@DyadicInc) May 15, 2024

DYAI under $2

same old same old,
he has to close a review deal

$DYAI

- The Street Podcast
- March 28th Financial Results & Conference Call
- Publication on Filamentous fungus-produced human monoclonal antibody

Links Below:

- https://thestreetreports.com/dyai-ceo-mark-emalfarb-shares-insights-6m-capital-raise-2024-outlook-etc-on-the-street-reports-podcast-tune-in/

- https://www.globenewswire.com/news-release/2024/03/14/2846716/0/en/Dyadic-to-Report-Full-Year-2023-Financial-Results-and-Host-Conference-call-on-Thursday-March-28-2024.html

- https://www.nature.com/articles/s41467-024-46443-0#Sec28

$DYAI CEO Mark Emalfarb Shares Insights, $6M Capital Raise, 2024 Outlook etc,. on “The Street Reports Podcast” – Tune In!

https://thestreetreports.com/dyai-ceo-mark-emalfarb-shares-insights-6m-capital-raise-2024-outlook-etc-on-the-street-reports-podcast-tune-in/

DYAI under $2

$DYAI Dyadic International, Inc Invites You to Join Us at The Microcap Conference


https://www.newsfilecorp.com/release/194733/Dyadic-International-Inc-Invites-You-to-Join-Us-at-The-Microcap-Conference

Jupiter, Florida--(Newsfile Corp. - January 22, 2024) - Dyadic International, Inc (NASDAQ: DYAI), Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health., will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

Ping Rawson, CFO, will be presenting on January 31 & February 1, 2024. Interested parties can register to attend here.

Members of the Dyadic International, Inc management team will also be conducting one-on-one meetings throughout the conference.

To register to attend The Microcap Conference, follow this link.

$DYAI "Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally"

https://www.marketscreener.com/quote/stock/DYADIC-INTERNATIONAL-INC-57599342/news/Dyadic-International-Inc-NASDAQ-DYAI-Advances-Biopharmaceutical-Innovations-and-Vaccine-Manufac-45617311/

Dyadic International Inc. (NASDAQ: DYAI), a leading biotechnology firm, focuses on developing innovative microbial platforms to address the increasing global demand for protein bioproduction. Furthermore, the company aims to fulfil unmet clinical and industrial needs by providing cost-effective, accessible, and efficient biopharmaceutical products for both human and animal applications.

Operating from the United States, this company has achieved success in developing a gene expression platform designed for the commercial synthesis of enzymes and various proteins. Utilizing this platform through licensing agreements, the company has leased it to Codexis, Inc. (NASDAQ: CDXS), BASF SE (OTCQX: BASFY, BASF.DE), Abengoa Bioenergy (OTC: AGOAF), and others in the past. In the past two years, the company has constructed another platform named Dapibus(TM), specifically designed to facilitate the production of metabolites, proteins, and other biological products for non-pharmaceutical applications.

Recently, Rubic One Health, the African licensee of Dyadic International, entered into an agreement with Afreximbank to secure funding for a vaccine manufacturing project facility. The vaccines will be produced utilizing Dyadic's C1 protein production platform, and manufacturing operations will take place in South Africa, with distribution planned across the entire continent.

Devoted to assisting its collaborators and partners in creating impactful therapeutic and preventive treatments, the company extends its support to partners in both developed and emerging nations. Dyadic International is actively advancing its microbial platform technologies, which encompass DYAI-100, its candidate for a COVID-19 vaccine. Concurrently, the company is engaged in the progression of additional biologic candidates and vaccines.

On November 20, a significant milestone occurred following the company's disclosure of a partnership agreement signed by Rubic One Health, its African licensee. Dyadic International conveyed that Rubic One Health had entered into an agreement with Afreximbank to secure funding for the project preparation facility dedicated to vaccine manufacturing. The announcement highlighted that the vaccines would be produced utilizing Dyadic's C1 protein production platform, with manufacturing operations set to take place in South Africa and distribution planned across the entire continent.

Additionally, the company broadened its pre-existing licensing arrangement with South African-based Rubic One Health. Under the terms of this extended agreement, Rubic is set to utilize Dyadic International's C1 platform for the exploration, development, and cost-effective, high-quality manufacturing of vaccines, catering to both human and animal use. The expanded licensing agreement emphasizes the distribution of these vaccines primarily in the African market. The recognition of the imperative to produce vaccines in Africa became evident with the signing of this deal by Rubic One Health.

Dyadic International, Inc. (NASDAQ: DYAI) is trading above is 30-day and 60-day averages at $1.58 and is position below its 20, 50, and 200-day moving averages, with a 52-week peak at $2.40, suggesting consolidation and signaling a potential transition to an upward trajectory. Considering these indicators, DYAI is a stock that warrants close monitoring in the current period and in the coming weeks.

$DYAI Some of the Best Ideas from the 12th Annual Benchmark Discovery Conference

https://www.nasdaq.com/articles/some-of-the-best-ideas-from-the-12th-annual-benchmark-discovery-conference

Conference season in the investment industry may be starting to wind down, but several reputable and well-known names have just wrapped up their annual conferences. One of the most recent conferences to wrap up was the Discovery Conference, hosted by The Benchmark Company. The annual conference gives companies opportunities for one-on-one meetings with institutional investors from across the U.S. Here are some of the best ideas from this year's Discovery Conference.

Dyadic

Dyadic (DYAI) is an interesting biotechnology company working on a wide range of products for human health, animal health and alternative proteins. First, the company is applying its proprietary and patented C1 technology to develop vaccines and antibodies for infectious diseases in humans.

During the first quarter, Dyadic began dosing in a Phase 1 clinical trial of DYAI-100, a COVID-19 booster vaccine candidate based on recombinant protein. The company expects the results from this first in-human trial to accelerate the adoption of the C1-cell protein production platform.

In addition to the COVID-19 vaccine, Dyadic is also developing several other vaccines for infectious diseases, including influenza, and other illnesses, including cancer. The company is using the same C1 platform to develop vaccines and antibodies for infectious diseases in animals, with a focus on Rift-Valley fever, salmonellosis, zoonotic influenza, West Nile virus, coronavirus, plague, rabies, Lyme disease and brucellosis.

Finally, Dyadic's alternative proteins program is aimed at reducing the cost of recombinant protein production using its proprietary Dapibus platform and other technologies in the search for non-pharmaceutical recombinant proteins. As part of this last program, Dyadic has launched a strategic partnership with a global food ingredient company and is exploring licensing and product opportunities in the alternative meat industry.

Investing in high-growth sectors

All the companies on this list operate in high-growth sectors and are developing cutting-edge technologies in their fields with the potential for tremendous gains in the future. For example, one estimate pegged the quantum-computing market at $812.6 million in revenue for 2022, with a projected compound annual growth rate (CAGR) of 22% between 2023 and 2030, bringing it to $8.2 billion in revenue.

Meanwhile, another estimate suggested the blood glucose monitoring device market was worth $12.5 billion in 2022 and projected a CAGR of 8.13% between 2023 and 2030. In fact, Know Labs could eventually address many more markets than just blood glucose monitoring with its technology, so these numbers probably represent only a fraction of the company’s potential total addressable market (TAM).

Ideal Power already addresses a large number of energy-efficient markets. However, one firm estimated that EVs alone represented a $49.1 billion market in 2022 and projected a CAGR of more than 15.5% between 2023 and 2032, making it worth $215.7 billion. Thus, Ideal Power’s TAM should be significantly larger than this one market alone.

Similarly, Dyadic is working on both vaccines and antibodies for infectious diseases and other illnesses in both humans and animals. However, considering only vaccines for infectious diseases, one estimate pegs the market at $77.6 billion in 2023 with a CAGR of 3.9% between 2023 and 2028, making it worth $93.8 billion.

Of course, despite the large TAMs these companies could see, investors are always advised to do their own due diligence before investing in any company or sector.

DYAI under $2

I think when people give up on a stock is the time to start buying.
HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target
i do not believe the $6 price target but I feel the risk reward is favorable and the story is good.

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
https://finance.yahoo.com/news/dyadics-dyai-100-covid-19-133000691.html
In summary, glycoprotein vaccine manufacturing C1 production platform appears
entirely suitable for rapid commercial development of SARS-CoV-2 vaccine, which would
be relatively unaffected by lack of resources, such as shortages of materials (e.g., plastic
bags for insect cell vaccine manufacturing), equipment, expensive media, and cold-chain
freezers. Based on the data of this study and further development under GMP conditions
for the first time, a subunit antigen vaccine produced in C1-cells received regulatory approval to initiate a Phase 1 clinical trial to demonstrate safety and efficacy in humans [55].
The above quote is taken from the published paper.

looks like it is taking the express train to a dollar?!

just another quarter of nothing really happening. Everyone is tired of all the people looking under. Wake me up when we get a buyer